Retrospective analysis of 156 cases of metastatic renal cell carcinoma: Evaluation of prognostic factors and response to different treatments

G. Landonio, C. Baiocchi, D. Cattaneo, M. Ferrari, O. Gottardi, M. Majno, E. Ghislandi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Metastatic renal cell carcinoma is a 'capricious' tumor. Many prognostic factors have been evaluated, treatment is still controversial, and results are not coincident. Methods: We reviewed 156 patients with metastatic renal cell carcinoma. Survival from the time of diagnosis was the end point of the study. The influence on survival of age, sex, nephrectomy, disease-free interval, performance status, site and number of metastases was analyzed. Univariate and multivariate analysis were done. Survival according to different therapies was also evaluated. Results: In our study, no nephrectomy, a disease-free interval <24 months, > 2 metastatic sites and a performance status > 2 proved to be risk factors. According to the number of risk factors, 3 groups of patients were identified (low, intermediate and high risk). We observed 3 kinds of responses to treatments: 1) in untreated patients (n = 48), median overall survival was 6 months, and the 24-month survival rate was 8%; 2) in patients treated with hormone therapy and/or chemotherapy (n = 73), median overall survival was 13 months, and the 24-month survival rate was 24%; 3) in patients treated with interferon and/or interleukin-2 (n = 35), median overall survival was 16 months and the 24-month survival rate was 34%. Conclusions: Our results are only partially in accordance with those observed by other authors. Risk factors and treatment must be determined in more defined and selected studies.

Original languageEnglish
Pages (from-to)468-472
Number of pages5
JournalTumori
Volume80
Issue number6
Publication statusPublished - 1994

Fingerprint

Renal Cell Carcinoma
Survival
Survival Rate
Nephrectomy
Therapeutics
Interferons
Interleukin-2
Multivariate Analysis
Hormones
Neoplasm Metastasis
Drug Therapy
Neoplasms

Keywords

  • metastatic renal cell carcinoma
  • prognostic factors
  • therapies

ASJC Scopus subject areas

  • Cancer Research

Cite this

Landonio, G., Baiocchi, C., Cattaneo, D., Ferrari, M., Gottardi, O., Majno, M., & Ghislandi, E. (1994). Retrospective analysis of 156 cases of metastatic renal cell carcinoma: Evaluation of prognostic factors and response to different treatments. Tumori, 80(6), 468-472.

Retrospective analysis of 156 cases of metastatic renal cell carcinoma : Evaluation of prognostic factors and response to different treatments. / Landonio, G.; Baiocchi, C.; Cattaneo, D.; Ferrari, M.; Gottardi, O.; Majno, M.; Ghislandi, E.

In: Tumori, Vol. 80, No. 6, 1994, p. 468-472.

Research output: Contribution to journalArticle

Landonio, G, Baiocchi, C, Cattaneo, D, Ferrari, M, Gottardi, O, Majno, M & Ghislandi, E 1994, 'Retrospective analysis of 156 cases of metastatic renal cell carcinoma: Evaluation of prognostic factors and response to different treatments', Tumori, vol. 80, no. 6, pp. 468-472.
Landonio, G. ; Baiocchi, C. ; Cattaneo, D. ; Ferrari, M. ; Gottardi, O. ; Majno, M. ; Ghislandi, E. / Retrospective analysis of 156 cases of metastatic renal cell carcinoma : Evaluation of prognostic factors and response to different treatments. In: Tumori. 1994 ; Vol. 80, No. 6. pp. 468-472.
@article{0863165f9c5f4e05be1b0ff8915373d5,
title = "Retrospective analysis of 156 cases of metastatic renal cell carcinoma: Evaluation of prognostic factors and response to different treatments",
abstract = "Background: Metastatic renal cell carcinoma is a 'capricious' tumor. Many prognostic factors have been evaluated, treatment is still controversial, and results are not coincident. Methods: We reviewed 156 patients with metastatic renal cell carcinoma. Survival from the time of diagnosis was the end point of the study. The influence on survival of age, sex, nephrectomy, disease-free interval, performance status, site and number of metastases was analyzed. Univariate and multivariate analysis were done. Survival according to different therapies was also evaluated. Results: In our study, no nephrectomy, a disease-free interval <24 months, > 2 metastatic sites and a performance status > 2 proved to be risk factors. According to the number of risk factors, 3 groups of patients were identified (low, intermediate and high risk). We observed 3 kinds of responses to treatments: 1) in untreated patients (n = 48), median overall survival was 6 months, and the 24-month survival rate was 8{\%}; 2) in patients treated with hormone therapy and/or chemotherapy (n = 73), median overall survival was 13 months, and the 24-month survival rate was 24{\%}; 3) in patients treated with interferon and/or interleukin-2 (n = 35), median overall survival was 16 months and the 24-month survival rate was 34{\%}. Conclusions: Our results are only partially in accordance with those observed by other authors. Risk factors and treatment must be determined in more defined and selected studies.",
keywords = "metastatic renal cell carcinoma, prognostic factors, therapies",
author = "G. Landonio and C. Baiocchi and D. Cattaneo and M. Ferrari and O. Gottardi and M. Majno and E. Ghislandi",
year = "1994",
language = "English",
volume = "80",
pages = "468--472",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Retrospective analysis of 156 cases of metastatic renal cell carcinoma

T2 - Evaluation of prognostic factors and response to different treatments

AU - Landonio, G.

AU - Baiocchi, C.

AU - Cattaneo, D.

AU - Ferrari, M.

AU - Gottardi, O.

AU - Majno, M.

AU - Ghislandi, E.

PY - 1994

Y1 - 1994

N2 - Background: Metastatic renal cell carcinoma is a 'capricious' tumor. Many prognostic factors have been evaluated, treatment is still controversial, and results are not coincident. Methods: We reviewed 156 patients with metastatic renal cell carcinoma. Survival from the time of diagnosis was the end point of the study. The influence on survival of age, sex, nephrectomy, disease-free interval, performance status, site and number of metastases was analyzed. Univariate and multivariate analysis were done. Survival according to different therapies was also evaluated. Results: In our study, no nephrectomy, a disease-free interval <24 months, > 2 metastatic sites and a performance status > 2 proved to be risk factors. According to the number of risk factors, 3 groups of patients were identified (low, intermediate and high risk). We observed 3 kinds of responses to treatments: 1) in untreated patients (n = 48), median overall survival was 6 months, and the 24-month survival rate was 8%; 2) in patients treated with hormone therapy and/or chemotherapy (n = 73), median overall survival was 13 months, and the 24-month survival rate was 24%; 3) in patients treated with interferon and/or interleukin-2 (n = 35), median overall survival was 16 months and the 24-month survival rate was 34%. Conclusions: Our results are only partially in accordance with those observed by other authors. Risk factors and treatment must be determined in more defined and selected studies.

AB - Background: Metastatic renal cell carcinoma is a 'capricious' tumor. Many prognostic factors have been evaluated, treatment is still controversial, and results are not coincident. Methods: We reviewed 156 patients with metastatic renal cell carcinoma. Survival from the time of diagnosis was the end point of the study. The influence on survival of age, sex, nephrectomy, disease-free interval, performance status, site and number of metastases was analyzed. Univariate and multivariate analysis were done. Survival according to different therapies was also evaluated. Results: In our study, no nephrectomy, a disease-free interval <24 months, > 2 metastatic sites and a performance status > 2 proved to be risk factors. According to the number of risk factors, 3 groups of patients were identified (low, intermediate and high risk). We observed 3 kinds of responses to treatments: 1) in untreated patients (n = 48), median overall survival was 6 months, and the 24-month survival rate was 8%; 2) in patients treated with hormone therapy and/or chemotherapy (n = 73), median overall survival was 13 months, and the 24-month survival rate was 24%; 3) in patients treated with interferon and/or interleukin-2 (n = 35), median overall survival was 16 months and the 24-month survival rate was 34%. Conclusions: Our results are only partially in accordance with those observed by other authors. Risk factors and treatment must be determined in more defined and selected studies.

KW - metastatic renal cell carcinoma

KW - prognostic factors

KW - therapies

UR - http://www.scopus.com/inward/record.url?scp=0028618495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028618495&partnerID=8YFLogxK

M3 - Article

C2 - 7900238

AN - SCOPUS:0028618495

VL - 80

SP - 468

EP - 472

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -